ERC Granted FDA Fast Track Designation for Sitoiganap in Patients with Recurrent Glioblastoma
July 26, 2022 01:00 ET
|
ERC-USA
ISNES, Belgium, July 26, 2022 (GLOBE NEWSWIRE) -- ERC Belgium S.A. (ERC), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sitoiganap® (Gliovac...
ERC Announces Publication of Positive Efficacy Data with Sitoiganap in Patients with Recurrent Glioblastoma
June 30, 2022 01:00 ET
|
ERC-USA
ISNES, Belgium, June 30, 2022 (GLOBE NEWSWIRE) -- ERC Belgium S.A. (ERC), announced publication of its most recent efficacy data in the May 2022 edition of Frontiers in Oncology. The authors...
ERC-USA Announces FDA Recommendation for Early Termination of Phase 2 Clinical Trial of ERC1671 (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma
April 07, 2021 08:12 ET
|
ERC-USA
IRVINE, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ERC-USA and the University of California, Irvine (UCI), today announce that the FDA has recommended early termination of the onging Phase 2...
ERC Launches Development Program for Novel Cell-Based Therapeutic and Prophylactic SARS-CoV-2 Vaccine
April 09, 2020 08:00 ET
|
ERC-USA
ISNES, Belgium, April 09, 2020 (GLOBE NEWSWIRE) -- ERC Worldwide today announced the launch of the Company’s development program for its therapeutic and prophylactic vaccine against the new...
ERC-USA Sponsors Ancillary Meeting to Discuss Outcomes from Its Clinical Trial and Right To Try Patient Experience of ERC1671 in Recurrent Glioblastoma
November 19, 2019 09:35 ET
|
ERC-USA
IRVINE, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- ERC-USA announces today it will be holding an ancillary meeting to discuss clinical outcomes of its Phase 2 clinical trial of ERC1671 in recurrent...
ERC-USA Initiates Therapy Under Right to Try Law With First Patient In California Using Investigational Compound ERC1671 for Treatment of Glioblastoma
January 08, 2019 09:35 ET
|
ERC-USA
IRVINE, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- ERC-USA and the University of California, Irvine have initiated treatment with the company’s investigational compound ERC1671, also known in Europe...